TRANSDERM-NITRO Drug Patent Profile

When do Transderm-nitro patents expire, and what generic alternatives are available?

Transderm-nitro is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in TRANSDERM-NITRO is nitroglycerin. There are thirty-six drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nitroglycerin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Transderm-nitro

A generic version of TRANSDERM-NITRO was approved as nitroglycerin by AM REGENT on May 24^th, 1988.

Summary for TRANSDERM-NITRO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	5
Patent Applications:	4,252
DailyMed Link:	TRANSDERM-NITRO at DailyMed

Recent Clinical Trials for TRANSDERM-NITRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Repurposed Therapeutics, Inc.	Phase 3
Naval Aeromedical Research Unit, Dayton	Phase 3
Repurposed Therapeutics, Inc.	Phase 2/Phase 3

See all TRANSDERM-NITRO clinical trials

US Patents and Regulatory Information for TRANSDERM-NITRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-002	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-003	Feb 27, 1996		DISCN	Yes	No
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-005	Feb 27, 1996		DISCN	Yes	No

Expired US Patents for TRANSDERM-NITRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-003	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996

International Patents for TRANSDERM-NITRO

See the table below for patents covering TRANSDERM-NITRO around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	162877
European Patent Office	0505013	Dispositif pour régler la vitesse de rotation d'un engin de terrassement (Apparatus for controlling rotational speed of prime mover of a construction machine)
United Kingdom	2100605	BANDAGE FOR ADMINISTERING DRUGS.
South Korea	940001934
Ireland	52931	BANDAGE FOR ADMINISTERING BENEFICIAL DRUG
Greece	75402

TRANSDERM-NITRO Market Analysis and Financial Projection

Last updated: April 25, 2026

Market Dynamics and Financial Trajectory for TRANSDERM-NITRO

What product is TRANSDERM-NITRO and where does it sit in the market?

TRANSDERM-NITRO is a transdermal nitroglycerin brand used for angina prophylaxis (chronic control) via steady systemic delivery. The formulation category is cardiovascular, not oncology or specialty biologics, and that shapes both demand stability and pricing behavior: payer coverage is typically entrenched, and conversion to generics can be decisive.

From a market-structure standpoint, transdermal nitroglycerin sits in a segment where:

• Therapeutic need is recurrent (ongoing cardiovascular risk management).
• Price competition intensifies when patents end and generics enter.
• Switching is often constrained by titration and tolerability, but still occurs once cheaper options gain formulary access.

How do demand and patient behavior drive sales?

Sales for transdermal nitroglycerin brands typically track a combination of:

• Prevalence of coronary artery disease and angina management (baseline demand).
• Adherence to chronic dosing schedules (transdermals often improve adherence vs. multiple daily oral nitrates).
• Formulary positioning within cardiovascular therapy classes (step therapy and preferred list dynamics).

Key behavioral characteristics that usually affect trajectory:

• Steady-state use: these products are used to prevent attacks rather than treat acute episodes.
• Dose-titration and patch comfort: real-world switching among products in the same drug class can be slower than pure “generic swap” in some markets because of tolerability and delivery-rate differences.

What competitive forces shape revenue growth or decline?

The dominant forces for TRANSDERM-NITRO-like products are classic small-molecule cardiovascular dynamics:

Force	Typical impact on a brand like TRANSDERM-NITRO	Why it matters financially
Generic erosion	Downward pressure once authorized generics or multiple competitor generics enter	Margin compression and share loss drive revenue decline
Formulary and rebate intensity	Shifts in payer preference can accelerate displacement	Net price can fall faster than list price
Manufacturing supply stability	Stock-outs or quality events reduce fill rates	Loss of continuity in chronic use affects prescriptions
Competitive patch delivery tech	Competes on tolerability and dosing convenience	Helps some products defend share longer, even as generics arrive

How do pricing and reimbursement trends behave for transdermal nitrates?

Pricing trajectory in this segment typically shows a “valley” pattern around exclusivity loss:

1. Pre-generic / limited competition: brand maintains higher net price through contracting leverage.
2. First generic entrants: net price drops quickly due to formulary switches.
3. Multiple generic coverage: further decline stabilizes at lower net price bands.

For cardiovascular cardiovascular transdermals, the base level of demand remains, but revenue growth becomes harder and profit pool shifts to the lowest-cost covered products.

What does the financial trajectory usually look like across the lifecycle?

For nitroglycerin transdermal brands, the financial trajectory typically follows four phases:

Lifecycle phase	Revenue behavior	Profit behavior	Dominant driver
Launch or re-launch	Growth with market penetration	Margin expansion if pricing holds	New patient starts and formulary inclusion
Steady brand period	Flat to modest growth	Stable margins	Contracting and steady adherence
Exclusivity loss / generic entry	Rapid revenue decline	Margin compression	Share loss and net price reductions
Settled generic era	Lower but more stable revenue	Low margins	Volume and purchasing decisions

Because TRANSDERM-NITRO is an established cardiovascular therapy, the market dynamics for its financial trajectory depend on whether it is currently in the “generic erosion” window or still protected by specific form/line exclusivities.

---

Exclusivity, Patent/Regulatory Headwinds, and Timing

What determines when TRANSDERM-NITRO loses exclusivity?

For transdermal nitroglycerin, exclusivity is typically fragmented across:

• Original active ingredient patent family expiry
• Product- or formulation-specific patents (patch structure, matrix, delivery rate control)
• Regulatory exclusivity (where available)
• Market authorization and interchangeability rules by jurisdiction

The market outcome is usually driven by what becomes substitutable at the pharmacy and what payers place on preferred lists.

What regulatory pathways affect entry speed of competitors?

Financial implications depend on how quickly competitors can launch after exclusivity:

• Generic pathway entry generally accelerates price erosion.
• Authorized generics can compress discount spreads by forcing broader pharmacy acceptance.
• Interchangeability and switching policies determine how fast volume migrates.

---

Market Share and Growth Levers

What levers can defend brand value after competition emerges?

Even in generic-heavy classes, brands can defend revenue longer through:

• Regional or payer-specific formulary placement (preferred status).
• Differentiation on dosing convenience and tolerability (reduced headaches, better skin comfort can slow switching).
• Manufacturing continuity that avoids lost scripts and patient drop-off.

Net effect: defense is usually relative, not absolute. Brands may hold volume longer, but net price trends remain downward.

---

Financial Trajectory: How to Read the Numbers Investors Use

Which financial metrics matter most for TRANSDERM-NITRO?

The financial trajectory for a transdermal nitroglycerin brand should be evaluated using:

1. Net revenue vs. prescriptions (volume)
   • Volume tends to hold up longer than net price.
2. Gross margin trend
   • Generic entry typically drives manufacturing cost dilution and pricing resets.
3. SG&A and rebate intensity
   • Payer contracting pressure can raise the cost to maintain share.
4. Operating income sensitivity
   • Small-molecule cardiovascular brands can remain profitable at lower prices if scale holds, but competition usually compresses operating leverage.

What patterns typically show up in P&L after generic entry?

A typical post-exclusivity profile for similar products:

• Revenue declines faster than volume if net price falls quickly.
• Operating income deteriorates even when manufacturing scale remains because rebates rise and margins drop.
• Cash flow stays positive if manufacturing is efficient and working capital is controlled, but reinvestment capacity weakens.

---

Business Implications: Investment and R&D Orientation

What does this mean for R&D strategy around TRANSDERM-NITRO-type assets?

If the goal is development or investment in nitroglycerin transdermal technology platforms, the practical lesson is that:

• Later-stage differentiation must be payer-relevant (tolerability, adherence, reduced discontinuation, lower total cost).
• Competitive advantage must survive interchangeability pressures, not only clinical endpoints.
• Value capture depends on life-cycle management (new strengths, dosing regimens, or patch technologies that remain meaningfully distinct).

For companies assessing pipeline or acquisitions in this class, the financial trajectory is less about new-to-market expansion and more about defending net pricing and holding volume during formulary re-contracting.

---

Key Takeaways

• TRANSDERM-NITRO is a transdermal nitroglycerin cardiovascular product, so its market dynamics are dominated by chronic demand, formulary contracting, and generic erosion.
• Its financial trajectory usually follows a lifecycle pattern: stable brand revenue pre-erosion, then steep net price and share decline after exclusivity loss, followed by a lower but more stable generic-era volume profile.
• The most investable signals are net revenue per prescription, rebate intensity, and operating leverage, since volume stability does not prevent margin compression.
• Post-competition defense is usually contract- and tolerability-driven, not novelty-driven: brands that remain preferred and reduce patient discontinuation tend to lose share more slowly.

---

FAQs

1. What drives sales for transdermal nitroglycerin brands like TRANSDERM-NITRO?
   Chronic angina prophylaxis demand, adherence to patch dosing, and formulary preference drive prescriptions and persistence.

2. Why do brand revenues fall faster than volumes in this category?
   Generic entry compresses net pricing through rebate pressure and payer switching, so revenue drops even when underlying patient demand remains.

3. What is the most important financial KPI post-exclusivity?
   Net revenue per prescription and operating margin, since pricing and rebate intensity typically deteriorate faster than volumes.

4. Can a brand defend market share after generic entry?
   Yes, if it retains preferred status and patients tolerate it well enough to reduce discontinuation and switching.

5. What type of differentiation matters commercially for patch therapies?
   Differentiation that improves tolerability and adherence enough to change formulary behavior and reduce discontinuation, not only pharmacokinetics.

---

References

[1] FDA. “NDA/ANDA Products.” U.S. Food and Drug Administration. https://www.fda.gov/drugs
[2] EMA. “Generic and Biosimilar Medicines.” European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/generic-biosimilar-medicines
[3] Lexicomp / Micromedex (clinical drug monographs). Transdermal nitroglycerin monographs and class information (accessed via institutional licensing).
[4] IQVIA Institute for Human Data Science. “Global Use of Medicines” and pharmaceutical market dynamics reporting (ongoing series). https://www.iqvia.com/insights/the-iqvia-institute